Dynamic global clinical
KlinEra guides sponsors to choose best model that focuses on the clinical development challenges of the study, increasing patient recruitment and retention and also expanding access to diverse patient populations.
KlinEra work in close collaboration to develop strategic, flexible approaches that leverage clinical informatics, state-of-the-art technologies, and global presence to maximise safety and efficiency and accurate data-driven for every study.
Our functional and therapeutic expertise includes Gastroenterology, Rheumatology, Cardio-metabolic, Oncology/Hematology, Infectious diseases, Neurology/Psychiatry, Rare disease, Respiratory, and Biosimilars.
Following are our list of services that demonstrates KlinEra’s end-to-end capabilities:
KlinEra has the experience and global resources to help plan and manage your most important clinical trials.
Our Clinical Research Associates (CRAs) are highly trained professionals who exercise ultimate efficiency in managing investigator sites and providing clinical trial monitoring services.
Project Management is our major competence. KlinEra own a set-up that is grounded upon project managers and skilled investigators with enormous experience who have the ability to efficiently lead projects from the start till end.
KlinEra Regulatory team provide comprehensive support for our Sponsors/Clients to overcome the hurdles linked with the requirements of the DCGI, FDA, EMA and Other Regulatory Bodies.
At KlinEra, we understand that quality must be intentionally performed, assessed, and promoted. KlinEra’s dedicated Quality and Compliance team have extensive experience in conducting all types of audits on a global basis.
Recognizing the critical importance of reliable and quality data in the clinical trial process, KlinEra provides comprehensive data management services for all phases of the clinical trial, emphasizing quality control and state-of-the-art technology.
Safety is imperative in clinical trials – new drugs and devices, no matter how innovative, cannot get to market unless proven to be safe for those who will use them.